# China NMPA Drug Inspection - Bozhou Yonggang Pharmaceutical Factory Co., Ltd. - Ginseng

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/bozhou-yonggang-pharmaceutical-factory-co-ltd/d1ea84af-85b9-4e58-9b3a-2560e738b52e/
Source feed: China

> China NMPA drug inspection for Bozhou Yonggang Pharmaceutical Factory Co., Ltd. published December 15, 2017. Drug: Ginseng. The State Administration for Market Regulation issued Announcement No. 206 in December 2017, detailing significant findi

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 206 of 2017 from the State Administration of Traditional Chinese Medicine regarding 39 batches of substandard prepared slices of traditional Chinese medicine.
- Company Name: Bozhou Yonggang Pharmaceutical Factory Co., Ltd.
- Publication Date: 2017-12-15
- Drug Name: Ginseng
- Inspection Finding: Pesticide residue levels not up to standard
- Action Taken: Control measures such as sealing and seizing have been taken, requiring the company to suspend sales and use, recall products, and rectify the situation. The relevant provincial food and drug administration departments will investigate the illegal production and sale of substandard drugs, publicly announce the results within three months, and may impose heavier penalties.
- Summary: The State Administration for Market Regulation issued Announcement No. 206 in December 2017, detailing significant findings regarding traditional Chinese medicine. Following extensive testing by the China National Institutes for Food and Drug Control, 39 batches of traditional Chinese medicine decoction pieces were identified as substandard. These unqualified products were produced by 34 enterprises, prominently including Jiangxi Bairen Traditional Chinese Medicine Decoction Pieces Co., Ltd., Beijing Bencao Fangyuan Pharmaceutical Co., Ltd., and Hebei Chufeng Traditional Chinese Medicine Pieces Co., Ltd. The primary violation involved the production and sale of these non-compliant medicinal items.

In response, provincial food and drug administration departments promptly implemented control measures, such as sealing and seizing the affected batches. The implicated companies were mandated to suspend sales and use, recall the substandard products, and undertake necessary rectifications. Operating under the regulatory framework of Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*, the State Food and Drug Administration (SFDA) has instructed provincial authorities to conduct thorough investigations into these illegal activities. Investigation results must be publicized within three months, with timely reporting to the SFDA. A formal process is also established for enterprises to dispute product authenticity, triggering further verification by regulatory bodies.

Company: https://www.globalkeysolutions.net/companies/bozhou-yonggang-pharmaceutical-factory-co-ltd/b33a5829-1d73-4a16-bc00-037896bb2b0e/